

2008 ANNUAL REVENUE OVER EXPECTATIONS, AT €4.1m (+62.4%)

Strong sales growth, markedly in the United States: +208.2%

Luminy, February 18 2009 - IPSOGEN (Alternext - FR0010626028 - ALIPS), a pioneer and key player in the development and marketing of molecular diagnostic tests for cancer, today announces its consolidated revenue for the financial year to December 31 2008.

| In €* | Dec. 31 '08 | Dec. 31 '07 | Δ | Δ at constant forex |
|-----------------------------------|------------------|------------------|---------------|---------------------|
| Revenue from Products | 3,884,475 | 2,059,601 | +88.6% | +93.1% |
| Revenue from Services | 240,536 | 480,045 | -49.9% | -49.9% |
| Total consolidated revenue | 4,125,011 | 2,539,646 | +62.4% | +66.1% |

* audited data, IFRS

2008 annual revenue totaled €4.1 million, up by more than 62.4% on the previous year and up 66.1% at constant forex. Revenue from Products, the Group' core business, grew by 88.6%, whilst revenue from the Group's Services activity, which the Company is continuing to pull out of, was down by close to 50%. Products activity now represents 94.2% of Group revenue, versus 81.1% in 2007.

The acceleration of our sales in North America (+208%) was confirmed, with annual revenue of 1.4 million at end-2008 versus €0.4 million at end-2007. Ipsogen Inc.'s revenue represented 33.2% of total Group revenue in 2008, versus 17.5% in 2007.

JAK2, with a more comprehensive product offer with the CE mark, obtained at the end of the first half of 2008, is continuing its strong development, with sales close to 50% of product revenue over the year.

Vincent Fert, President and CEO, states: "2008 was a quite successful year, both on the financial side, with the success of our IPO, and on the business development side: in addition to the sharp acceleration of our product sales, our portfolio of hematological and breast cancer products now includes 33 biomarkers of clinical interest and our penetration of the North American market is very promising.

The revenue growth in 2008, with a significant acceleration over the second half, was above market expectations, and confirms our positioning on the high-potential cancer molecular diagnosis market. Backed by our healthy balance sheet situation, we are entering this new year of buoyant growth with serenity."



About IPSOGEN

Ipsogen, Cancer Profiler, develops and markets molecular diagnostic tests designed to map diseases in order to guide patients and oncologists decisions along their complex therapeutic path.

With more than 70 tests already used routinely worldwide for the diagnosis, prognosis and follow-up of thousands of patients with leukemia, Ipsogen is now also targeting breast cancer. Its initial goal will be to provide diagnostic information that remained unavailable until now.

Strengthened by its first-rate scientific, clinical and technological partnerships, in addition to its highly-skilled multidisciplinary team in France and the USA, Ipsogen is striving to become the leader in the molecular profiling of cancers. It is pursuing its development and promotion of diagnostic standards that have a significant impact on patients, medical professionals and society.

Ipsogen employed 48 people as of December 31, 2008. Its headquarters are located in Marseille, France.

The company has also a subsidiary, Ipsogen Inc., in New Haven, CT, USA.

For more information, visit: www.ipsogen.com

Contacts

| | | |
|--|--|--|
| <p>IPSOGEN Vincent Fert President & CEO Tel.: + 33 (0)4 9129 3090 fert@ipsogen.com</p> <p>Stanislas Piot CFO Tel.: + 33 (0)4 9129 3090 piot@ipsogen.com</p> | <p>ATCG Press Corporate & Product Information</p> <p>Marielle Bricman Tel.: + 33 (0)4 9125 0785 ipsogen@atcg-partners.com</p> | <p>NewCap. Financial Communication and Investor Relations</p> <p>Axelle Vuillermet & Pierre Laurent Tel.: + 33 (0)1 44 71 94 93 ipsogen@newcap.fr</p> |
|--|--|--|

**Publication of 2008 annual results:
March 18 2008 (before market)**